Although the role of tumor immunity has been known for decades [2], the introduction of immune checkpoint inhibitors (e.g., anti-CTLA4, or PD1/PDL1 axis antagonists) as new anticancer agents quickly led to spectacular improvements in clinical outcomes, including 5 year-survival rates above 30%. The gene discussed is CTLA4; the disease is neoplasm.